MedTrace Logo

Efficacy, Safety, and Immunogenicity of Vaccine Reimmunization With a Third Homologous Versus Heterologous Dose Against COVID-19 in Patients Undergoing Solid Organ Transplantation.

NCT05048940 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2023-03-02

No results posted yet for this study

Summary

Patients undergoing solid organ transplantation randomly selected from those who have received two doses of Spikevax (Moderna) vaccine, provided that a minimum of 8 weeks have elapsed from the second dose to the time of the start of the trial. It is planned to include 386 patients.

Conditions

  • Covid19

Interventions

BIOLOGICAL

Janssen vaccine

0.5 ml millilitre(s) Intramuscular use

BIOLOGICAL

Spikevax (Moderna) vaccine

0.5 ml millilitre(s) Intramuscular use

Sponsors & Collaborators

  • Instituto de Investigación Marqués de Valdecilla

    lead OTHER

Principal Investigators

  • Javier Crespo García · Hospital Universitario Marqués de Valdecilla

  • Marcos López Hoyos · Hospital Universitario Marqués de Valdecilla

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-09-01
Primary Completion
2021-09-01
Completion
2021-09-01

Countries

  • Spain

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05048940 on ClinicalTrials.gov